PI
PTCT icon

PFS Investments’s PTC Therapeutics PTCT Stock Holding History

PFS Investments’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$246K Buy
6,055
+578
+11% +$28.3K ﹤0.01% 470
2023
Q1 		$267K Buy
+5,477
New +$250K ﹤0.01% 449

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

PFS Investments's PTCT Position: Q2 2023 in Review

PFS Investments increased its PTC Therapeutics (PTCT) stake by 11% in Q2 2023, buying an estimated $28.3K and bringing the position to 6,055 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

PFS Investments first reported a position in PTCT in Q1 2023 and has held it in 2 quarters since. The position peaked at $267K in Q1 2023. 205 funds tracked by Wall St. Rank hold PTCT as of Q2 2023.

  • PFS Investments held 6,055 shares of PTC Therapeutics worth $246K as of Q2 2023.
  • PFS Investments bought 578 PTC Therapeutics shares in Q2 2023, an estimated $28.3K.
  • PTC Therapeutics made up ﹤0.01% of PFS Investments's portfolio in Q2 2023, its #470 holding.
  • PFS Investments first reported a position in PTC Therapeutics in Q1 2023 and has held it in 2 quarters since.
  • PFS Investments's PTC Therapeutics position peaked at $267K in Q1 2023.
  • 205 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2023.

Based on PFS Investments's 13F filing for Q2 2023, filed 14 Aug 2023.